Events leading to discontinuation in olaparib, niraparib and rucaparib groups
| AEs leading to discontinuation | Olaparib | Niraparib | Rucaparib | |||
| SOLO2 | SOLO1 | NOVA | PRIMA | ARIEL3 | ATHENA | |
| Blood and lymphatic system disorders | ||||||
| Anemia | 6 (3.1%) | 6 (2.3%) | 5 (1.4%) | 9 (1.9%) | 11 (3.0%) | 115 (27.1%) |
| Neutropenia | 3 (1.5%) | 2 (0.8%) | 7 (1.9%) | 9 (1.9%) | 5 (1.3%) | 63 (14.8%) |
| Leukopenia | 1 (0.5%) | 1 (0.4%) | 7 (1.9%) | 10 (2.1%) | 1 (0.3%) | 16 (3.8%) |
| Thrombocytopenia | 1 (0.5%) | 1 (0.4%) | 12 (3.3%) | 21 (4.3%) | 10 (2.7%) | 45 (10.6%) |
| Pancytopenia | 0 | 3 (0.8%) | – | 1 (0.3%) | – | |
| Acute myeloid leukemia | 1 (0.5%) | 0 | – | – | 1 (0.3%) | – |
| Myelodysplastic syndrome | 1 (0.5%) | 0 | – | – | 2 (0.5%) | – |
| Gastrointestinal disorders | ||||||
| Gastric cancer/oral cavity | 1 (0.5%) | 1 (0.4%) | – | – | 0 | – |
| Abdominal pain | 1 (0.5%) | 1 (0.4%) | – | – | 1 (0.3%) | – |
| Nausea | 1 (0.5%) | 6 (2.3%) | – | – | 9 (2.4%) | 38 (8.9%) |
| Vomiting | 0 | 2 (0.8%) | – | – | 5 (1.3%) | 19 (4.5%) |
| Dyspepsia | 0 | 1 (0.4%) | – | – | 1 (0.3%) | – |
| General disorders | ||||||
| Asthenia/fatigue | 0 | 6 (2.3%) | – | – | 6 (1.6%) | 41 (9.6%) |
| Edema peripheral | 1 (0.5%) | – | – | 0 | – | |
| Fever | 0 | 1 (0.4%) | – | – | – | |
| Disturbance in attention | 1 (0.5%) | 1 (0.4%) | – | – | 1 (0.3%) | – |
| Decreased appetite | 0 | 1 (0.4%) | – | – | 7 (1.6%) | |
| Infections | ||||||
| Pneumonitis | 1 (0.5%) | 1 (0.4%) | – | – | 0 | – |
| Investigations | ||||||
| Increased ALT/AST | 0 | – | – | 2 (0.5%) | 49 (11.5%) | |
| Acute kidney injury | 0 | – | – | 2 (0.5%) | – | |
| Musculoskeletal | ||||||
| Muscular weakness | 1 (0.5%) | 2 (0.8%) | – | – | 0 | – |
| Pain in extremity | 1 (0.5%) | 1 (0.4%) | – | – | 0 | – |
| Nervous system | ||||||
| Depression | 1 (0.5%) | 1 (0.4%) | – | – | 0 | – |
| Skin | ||||||
| Dermatitis (allergic) | 1 (0.5%) | 0 | – | – | 0 | – |
| Respiratory | ||||||
| Dyspnea | 0 | 1 (0.4%) | – | – | 1 (0.3%) | 8 (1.9%) |
| Others | ||||||
| Invasive breast carcinoma | 0 | 1 (0.4%) | – | – | 0 | – |
| Cardiac arrest | 0 | – | – | 1 (0.3%) | – | |
AEs, adverse events.